U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H11N3O3S
Molecular Weight 253.2791
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFAMETHOXAZOLE

SMILES

Cc1cc(no1)NS(=O)(=O)c2ccc(cc2)N

InChI

InChIKey=JLKIGFTWXXRPMT-UHFFFAOYSA-N
InChI=1S/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13)

HIDE SMILES / InChI
Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.71 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Curative
BACTRIM

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, Bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.

Launch Date

1.12752001E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
94.42 μg/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETHOXAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
46.3 μg/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TRIMETHOPRIM
SULFAMETHOXAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1202.5 μg × h/mL
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SULFAMETHOXAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.8 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TRIMETHOPRIM
SULFAMETHOXAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered: TRIMETHOPRIM
SULFAMETHOXAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Insomnia...
Other AEs: Fear, Behaviour abnormal...
AEs leading to
discontinuation/dose reduction:
Insomnia
Other AEs:
Fear
Behaviour abnormal
Visual hallucinations
Disorientation
Auditory hallucinations
Sources:
1600 mg multiple, oral
Recommended
Dose: 1600 mg
Route: oral
Route: multiple
Dose: 1600 mg
Co-administed with::
TRIMETHOPRIM(320 mg; daily)
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: renal transplantation
Age Group: adult
Population Size: 14
Sources:
Other AEs: Leucopenia...
Other AEs:
Leucopenia
Sources:
2400 mg 1 times / day single, oral
Highest studied dose
Dose: 2400 mg, 1 times / day
Route: oral
Route: single
Dose: 2400 mg, 1 times / day
Co-administed with::
TRIMETHOPRIM(480 mg; single)
Sources:
unhealthy, mean age 20 years
n = 31
Health Status: unhealthy
Condition: urinary tract infection
Age Group: mean age 20 years
Sex: F
Population Size: 31
Sources:
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(240 mg; 2/day)
amphotericin B(800 mg; day)
Sources:
unhealthy, mean age 47 years
n = 26
Health Status: unhealthy
Condition: acute nonlymphocytic leukaemia
Age Group: mean age 47 years
Population Size: 26
Sources:
Disc. AE: Allergic reaction...
Other AEs: Granulocytopenia...
AEs leading to
discontinuation/dose reduction:
Allergic reaction (3.8%)
Other AEs:
Granulocytopenia
Sources:
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, mean age 58 years
n = 41
Health Status: unhealthy
Condition: urinary infection
Age Group: mean age 58 years
Sex: M+F
Population Size: 41
Sources:
Disc. AE: Skin rash...
AEs leading to
discontinuation/dose reduction:
Skin rash (4.9%)
Sources:
1200 mg multiple, oral (mean)
Studied dose
Dose: 1200 mg
Route: oral
Route: multiple
Dose: 1200 mg
Co-administed with::
TRIMETHOPRIM(240 mg; day)
Sources:
unhealthy, median age 69 years
n = 91
Health Status: unhealthy
Condition: septicemia
Age Group: median age 69 years
Sex: M+F
Population Size: 91
Sources:
Other AEs: Agranulocytosis...
Other AEs:
Agranulocytosis (9.9%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Auditory hallucinations
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Behaviour abnormal
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Disorientation
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Fear
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Visual hallucinations
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Insomnia Disc. AE
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, 86 years
n = 1
Health Status: unhealthy
Condition: lower urinary infection
Age Group: 86 years
Sex: F
Population Size: 1
Sources:
Leucopenia
1600 mg multiple, oral
Recommended
Dose: 1600 mg
Route: oral
Route: multiple
Dose: 1600 mg
Co-administed with::
TRIMETHOPRIM(320 mg; daily)
Sources:
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: renal transplantation
Age Group: adult
Population Size: 14
Sources:
Granulocytopenia
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(240 mg; 2/day)
amphotericin B(800 mg; day)
Sources:
unhealthy, mean age 47 years
n = 26
Health Status: unhealthy
Condition: acute nonlymphocytic leukaemia
Age Group: mean age 47 years
Population Size: 26
Sources:
Allergic reaction 3.8%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(240 mg; 2/day)
amphotericin B(800 mg; day)
Sources:
unhealthy, mean age 47 years
n = 26
Health Status: unhealthy
Condition: acute nonlymphocytic leukaemia
Age Group: mean age 47 years
Population Size: 26
Sources:
Skin rash 4.9%
Disc. AE
800 mg 2 times / day multiple, oral
Recommended
Dose: 800 mg, 2 times / day
Route: oral
Route: multiple
Dose: 800 mg, 2 times / day
Co-administed with::
TRIMETHOPRIM(160 mg; 2/day)
Sources:
unhealthy, mean age 58 years
n = 41
Health Status: unhealthy
Condition: urinary infection
Age Group: mean age 58 years
Sex: M+F
Population Size: 41
Sources:
Agranulocytosis 9.9%
1200 mg multiple, oral (mean)
Studied dose
Dose: 1200 mg
Route: oral
Route: multiple
Dose: 1200 mg
Co-administed with::
TRIMETHOPRIM(240 mg; day)
Sources:
unhealthy, median age 69 years
n = 91
Health Status: unhealthy
Condition: septicemia
Age Group: median age 69 years
Sex: M+F
Population Size: 91
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: ketoconazole did not inhibit hydroxylamine formation or any route of SMX metabolism; fluconazole decreased 5OH-SMX-acetate by64.0%
Page: 3.0
PubMed

PubMed

TitleDatePubMed
Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals.
2000 Jun 15
The importance of the removal of the intrauterine device in genital colonization by actinomyces.
2001
Molecular characterization of Salmonella weltevreden isolated from poultry: evidence of conjugal transfer of plasmid and antibiotic resistance.
2001
Infrared studies on Co and Cd complexes of sulfamethoxazole.
2001 Apr
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.
2001 Apr 28
Practice guidelines for the treatment of uncomplicated cystitis.
2001 Aug
Circadian changes in pharmacokinetics of sulfamethoxazole administered orally to rabbits.
2001 Aug
Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single- and multiple-dose administration to healthy pigs.
2001 Aug
Effect of lipopolysaccharide (LPS)-evoked host defense activation on hepatic microsomal formation and reduction of sulfamethoxazole hydroxylamine in the rat.
2001 Aug 15
Resistance to trimethoprim-sulfamethoxazole and modifications in genes coding for dihydrofolate reductase and dihydropteroate synthase in European Streptococcus pneumoniae isolates.
2001 Dec
Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple-drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons.
2001 Dec
Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells.
2001 Feb
Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones.
2001 Jul
Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
2001 Jun
Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.
2001 Jun 1
Indirect potentiometric titration of sulphamethoxazole in the presence of trimethoprim in co-trimazole tablets using copper based mercury film electrode.
2001 Mar
Topical bactrim versus trimethoprim and sulfonamide against nocardia keratitis.
2001 Mar
Randomized intervention study comparing several regimens for the treatment of moderate anemia among refugee children in Kigoma Region, Tanzania.
2001 Mar-Apr
A suspected case of primary cutaneous actinomycosis on the buttock.
2001 May
Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.
2001 May
Determination of sulfametoxazole, sulfadiazine and associated compounds in pharmaceutical preparations by capillary zone electrophoresis.
2001 May 18
Paraplegia secondary to Burkholderia pseudomallei myelitis: a case report.
2001 Nov
Design and evaluation of drug-loaded wound dressing having thermoresponsive, adhesive, absorptive and easy peeling properties.
2001 Nov
Plasmid mediated antibiotic resistance in Klebsiella pneumoniae.
2001 Oct
Antimicrobial susceptibility and plasmids from Escherichia coli isolated from rats.
2001 Oct
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
2001 Oct
Cotrimoxazole treatment for rheumatoid arthritis.
2001 Oct
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000.
2002
Determination of selected sulfonamide antibiotics and trimethoprim in manure by electrospray and atmospheric pressure chemical ionization tandem mass spectrometry.
2002
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen.
2002 Apr
Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation.
2002 Apr
Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient.
2002 Apr
Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.
2002 Apr
Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.
2002 Apr 15
Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography-mass spectrometry.
2002 Apr 5
Determination of anti-microbial susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis.
2002 Feb
Role of endotoxin in 6-sulfanilamidoindazole(6SAI)-induced arthritis in rats.
2002 Feb
Folic acid antagonism of sulfa drug treatments.
2002 Feb
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.
2002 Jan
Liquid chromatographic determination of multiple sulfonamides, nitrofurans, and chloramphenicol residues in pasteurized milk.
2002 Jan-Feb
Sensitivity and resistance of antibiotics in common infection of male and female.
2002 Jan-Mar
Current treatment options for chronic granulomatous disease.
2002 Jul
Ofuji's disease: a report on 20 patients with clinical and histopathologic analysis.
2002 Jun
Second derivative spectrophotometric determination of trimethoprime and sulfamethoxazole in the presence of hydroxypropyl-beta-cyclodextrin (HP-beta-CD).
2002 Jun 20
Septicaemic pasteurellosis in ostriches (Struthio camelus) in central Saudi Arabia.
2002 Mar
Pharmacokinetics of sulfamethoxazole and trimethoprim in donkeys, mules, and horses.
2002 Mar
Iminodibenzyl as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.
2002 Mar
[Characterization of Vibrio cholerae eltor in the city of Kazan in 2001].
2002 Mar-Apr
Patents

Sample Use Guides

The usual adult dosage in the treatment of urinary tract infections and otitis media is 1 DS (double strength) tablet (each DS tablets contains 800 mg sulfamethoxazole and 160 mg trimethoprim) every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.The usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 1 DS tablet every 12 hours for 14 days. The recommended dosage for treatment of patients with documented Pneumocystis jiroveci pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days. The recommended dosage for prophylaxis in adults is 1 DS tablet daily. For the treatment of traveler’s diarrhea, the usual adult dosage is 1 DS tablet every 12 hours for 5 days.
Route of Administration: Oral
Bacterias were treated with 23.75 ug sulfamethoxazole to test the susceptibility of microorganisms. MIC values were 38 mcg/ml (Enterobacteriaceae), 9.5 mcg/ml (Haemophilus influenzae), 9.5 mcg/ml (Streptococcus pneumoniae).
Name Type Language
SULFAMETHOXAZOLE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
RO 4-2130
Code English
SULFAMETHOXAZOLE COMPONENT OF UROPLUS
Common Name English
SULFAMETHOXAZOLE [INN]
Common Name English
SULFAMETHOPRIM COMPONENT SULFAMETHOXAZOLE
Common Name English
UROPLUS COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE [USP]
Common Name English
NSC-147832
Code English
COTRIM COMPONENT SULFAMETHOXAZOLE
Common Name English
COTRIM D.S. COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE COMPONENT OF COTRIM D.S.
Common Name English
SULFAMETHOXAZOLE COMPONENT OF BACTRIM PEDIATRIC
Common Name English
GANTANOL
Brand Name English
SULFAMETHOXAZOLE [USP-RS]
Common Name English
AZO GANTANOL COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE [MART.]
Common Name English
BACTRIM PEDIATRIC COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE COMPONENT OF COTRIM
Common Name English
SULFAMETHOXAZOLE COMPONENT OF SULFAMETHOPRIM
Common Name English
SEPTRA COMPONENT SULFAMETHOXAZOLE
Common Name English
STX-608
Code English
SULFAMETHOXAZOLE [ORANGE BOOK]
Common Name English
SULFAMETHOXAZOLUM [WHO-IP LATIN]
Common Name English
SULFAMETHOXAZOLE COMPONENT OF BACTRIM DS
Common Name English
BACTRIM DS COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE [WHO-DD]
Common Name English
SULFAMETHOXAZOLE [JAN]
Common Name English
SULFAMETHOXAZOLE COMPONENT OF BACTRIM
Common Name English
SULFAMETHOXAZOLE COMPONENT OF SEPTRA
Common Name English
SULFATRIM COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE [VANDF]
Common Name English
BACTRIM COMPONENT SULFAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE [IARC]
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-(5-METHYL-3-ISOXAZOLYL)-
Systematic Name English
SULFAMETHOXAZOLE COMPONENT OF SULMEPRIM
Common Name English
SULPHAMETHOXAZOLE
Common Name English
SULFAMETHOXAZOLE COMPONENT OF SULFATRIM
Common Name English
SULFAMETHOXAZOLE [USAN]
Common Name English
RO-4-2130
Code English
SULFAMETHOXAZOLE [MI]
Common Name English
SULMEPRIM COMPONENT SULFAMETHOXAZOLE
Common Name English
N(SUP 1)-(5-METHYL-3-ISOXAZOLYL)SULFANILAMIDE
Systematic Name English
SULFAMETHOXAZOLE COMPONENT OF AZO GANTANOL
Common Name English
SULFAMETHOXAZOLE [HSDB]
Common Name English
SMX
Common Name English
SULFAMETHOXAZOLE [EP MONOGRAPH]
Common Name English
SULFAMETHOXAZOLE [WHO-IP]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 6.5.4 (SUL/TRI)
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.2 (SUL/TRI)
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
NDF-RT N0000008048
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-ATC J01EE01
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-VATC QJ01EQ11
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-VATC QJ01EW11
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
NCI_THESAURUS C29739
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
NDF-RT N0000008048
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
LIVERTOX 911
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
NDF-RT N0000175504
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-ATC J04AM08
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
WHO-ATC J01EC01
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
NDF-RT N0000008048
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
Code System Code Type Description
LACTMED
Sulfamethoxazole
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
EPA CompTox
723-46-6
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
FDA UNII
JE42381TNV
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
WIKIPEDIA
SULFAMETHOXAZOLE
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
DRUG CENTRAL
2514
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
EVMPD
SUB10711MIG
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
NCI_THESAURUS
C47737
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
RXCUI
10180
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
SULFAMETHOXAZOLE
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY Description: A white or yellowish white, crystalline powder; odourless. Solubility: Very slightly soluble in water; soluble in 50 parts of ethanol (~750 g/l) TS and in 3 parts of acetone R. Category: Antibacterial. Storage: Sulfamethoxazole should be kept in a well-closed container, protected from light. Definition: Sulfamethoxazole contains not less than 99.0% and not more than 101.0% of C10H11N3O3S, calculated with reference to the dried substance.
NDF-RT
N0000185504
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
ECHA (EC/EINECS)
211-963-3
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
MESH
D013420
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
HSDB
3186
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
ChEMBL
CHEMBL443
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
PUBCHEM
5329
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
INN
1386
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
USP_CATALOG
1631001
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB01015
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
CAS
723-46-6
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
LACTMED
Trimethoprim-Sulfamethoxazole
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY
MERCK INDEX
M10320
Created by admin on Fri Jun 25 21:20:19 UTC 2021 , Edited by admin on Fri Jun 25 21:20:19 UTC 2021
PRIMARY Merck Index